Edward A. Fox
#187,007
Most Influential Person Now
Edward A. Fox's AcademicInfluence.com Rankings
Edward A. Foxcomputer-science Degrees
Computer Science
#12217
World Rank
#13027
Historical Rank
Information Management
#146
World Rank
#148
Historical Rank
Database
#9273
World Rank
#9761
Historical Rank
Download Badge
Computer Science
Why Is Edward A. Fox Influential?
(Suggest an Edit or Addition)Edward A. Fox's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Genome-wide analysis of estrogen receptor binding sites (2006) (1388)
- Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 (2005) (1341)
- Biallelic Inactivation of BRCA2 in Fanconi Anemia (2002) (1222)
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005) (696)
- Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. (2005) (545)
- Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. (2010) (464)
- c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. (2003) (449)
- Germ-line msh6 mutations in colorectal cancer families. (1999) (349)
- Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families (1996) (313)
- Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. (1989) (269)
- FLT3 mutations in childhood acute lymphoblastic leukemia. (2004) (256)
- Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. (2007) (253)
- Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. (2004) (232)
- Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations inMSH2 and MLH1 (2000) (223)
- Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. (2002) (200)
- Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2006) (177)
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms (2011) (166)
- Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development (2001) (154)
- Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. (1999) (145)
- Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. (2004) (139)
- Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms (2011) (132)
- Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs (2014) (131)
- Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays (2007) (125)
- Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. (1989) (120)
- XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient mice. (2006) (113)
- Genomic mapping of RNA polymerase II reveals sites of co-transcriptional regulation in human cells (2005) (103)
- Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. (2001) (100)
- Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. (2005) (97)
- Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. (2004) (96)
- Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. (1996) (91)
- Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. (2008) (89)
- Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF) (2005) (84)
- Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. (2012) (82)
- A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets (2013) (81)
- Expression of Met-(-1) angiogenin in Escherichia coli: conversion to the authentic less than Glu-1 protein. (1988) (80)
- Molecular characterization and phylogenetic studies of a wound-inducible proteinase inhibitor I gene in Lycopersicon species. (1986) (73)
- Primary structure of human placental ribonuclease inhibitor. (1988) (72)
- Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias (2006) (68)
- Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia (2011) (66)
- Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer (2011) (55)
- Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1 (2000) (54)
- Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells (2011) (50)
- PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. (2004) (42)
- cDNA sequence of human class III alcohol dehydrogenase. (1989) (41)
- Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. (2008) (41)
- Exon expression profiling reveals stimulus-mediated exon use in neural cells (2007) (40)
- NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. (2014) (39)
- Localization of the human angiogenin gene to chromosome band 14q11, proximal to the T cell receptor alpha/delta locus. (1990) (34)
- Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy (2007) (31)
- FLT 3 mutations in childhood acute lymphoblastic leukemia (2004) (30)
- T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. (1997) (25)
- Genetic fixity in the human major histocompatibility complex and block size diversity in the class I region including HLA-E (2007) (24)
- Avian alcohol dehydrogenase: the chicken liver enzyme. Primary structure, cDNA-cloning, and relationships to other alcohol dehydrogenases. (1990) (24)
- Microarray blob-defect removal improves array analysis (2007) (23)
- Mutagenesis of residues flanking Lys-40 enhances the enzymatic activity and reduces the angiogenic potency of angiogenin. (1990) (22)
- IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM). (2006) (22)
- c-MET expression/activation, functions, and mutations in non-small cell lung cancer (2004) (21)
- Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia (2009) (19)
- Highly selective isolation of unknown mutations in diverse DNA fragments: toward new multiplex screening in cancer. (2000) (19)
- Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors (2010) (18)
- Accurate, high-throughput "snapshot" detection of hMLH1 mutations by two-dimensional DNA electrophoresis. (1998) (18)
- Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer (2003) (18)
- Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. (2007) (17)
- Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations (2010) (16)
- Germ-line msh 6 Mutations in Colorectal Cancer Families 1 (1999) (14)
- Characterization, expression and envelope association of a Chlamydia trachomatis 28 kDa protein. (1995) (13)
- Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. (2011) (11)
- Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD (2011) (10)
- The placental ribonuclease inhibitor (RNH) gene is located on chromosome subband 11p15.5. (1990) (9)
- Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes (2012) (8)
- Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab. (2005) (8)
- Erratum: Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays (PLoS Computational Biology 2, 5, doi:10.1371/journal.pcbi.0020041) (2007) (7)
- Molecular Analysis of DNA Rearrangements in Leukemias and Non‐Hodgkin's Lymphomas (1994) (6)
- The previously identified r3/r5 repressor may require the cooperation of additional negative elements for rhombomere restriction of Hoxb1. (2000) (6)
- Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients. (1998) (5)
- Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML (2004) (5)
- A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML) (2012) (4)
- O-306 Novel somatic mutations in the juxtamembrane domain of c-Met in small cell lung cancer: implications in cytoskeletal functions and cell motility (2003) (3)
- Polymorphisms in FcγRIIIA Are Genetically Linked to FcγRIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in FcγRIIIA-158 in Determining Rituximab Responses. (2005) (2)
- Next Generation Sequencing Identifies Novel Oncogene Alterations In CRLF2-rearranged Precursor B-Cell Acute Lymphoblastic Leukemia (2010) (2)
- The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM) (2010) (2)
- Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenstrom’s Macroglobulinemia. (2005) (2)
- Localization of the Human Angiogenin Gene to Chromosome Band 14qll1, Proximal to the T Cell Receptor a/8 Locus (2006) (2)
- Inferring Loss-of-Heterozygosity From Tumor-only Samples Using High-Density Oligonucleotide SNP Arrays (2)
- Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML) (2010) (1)
- Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets (2011) (1)
- Genetic Linkage of FcγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy (2007) (1)
- Trisomy of the Down Syndrome Critical Region Suppresses Precursor B-Cell Differentiation and Promotes B-Cell Transformation Associated with Altered Expression of Polycomb Repressor Complex 2 Targets (2012) (1)
- Small Cell Lung Cancer − RNA in Non Therapeutic Inhibition with SU 11274 and Small Interfering Functional Expression and Mutations of c-Met and Its (2005) (1)
- Genome Wide Association Studies of Familial Waldenstrom's Macroglobulinemia (WM) Reveals a Loss of GSTM1 Is Common in Families with a History of B-Cell Disorders but Not in Those with a History Specific for WM. (2009) (1)
- respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3 (2013) (1)
- Primary structure of human placental ribonuclease inhibitor [Erratum to document cited in CA109(23):207334b] (1989) (1)
- Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstrom’s Macroglobulinemia (WM). (2005) (1)
- Genome-wide analysis of HIF-1 binding with chromatin immunoprecipitation and tiled microarray (2007) (0)
- PKC 412 FLT3 inhibitor therapy in AML (2004) (0)
- Molecular cloning of human testicular angiotensin-converting enzyme : The testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme ( polymerase chain reaction / alternative splicing ) (0)
- Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation, (2011) (0)
- O-193 Novel semaphorin- and juxtamembrane-domain mutations ofc-MET in NSCLC: Potential for targeted inhibition (2005) (0)
- Molecular Cancer apeutics apeutic Discovery overy and Characterization of Novel Mutant Ther 3 Kinase Inhibitors (2010) (0)
- Inferring Loss-of-Heterozygosity from Tumors Without Paired Normals Using High-Density SNP Arrays (2005) (0)
- Comparison of High Dose Chemotherapy with Autologous Stem Cell Rescue (ASCT) Versus Consolidation Chemotherapy for Patients < 60 with Cytogenetically Normal AML (CN-AML) and Flt3 ITD (2010) (0)
- Prevalence of factor V Leiden among women with pulmonary embolism or deep vein thrombosis during pregnancy or oral contraceptive use (1996) (0)
- Molecular characterization andphylogenetic studies ofa wound-inducible proteinase inhibitor IgeneinLycopersicon species (1986) (0)
- Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status (2010) (0)
- Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia. (2009) (0)
- FLT3 Tyrosine Kinase in AML Identification and Characterization of a Novel Activating Mutation of the (2012) (0)
- Correction: Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2007) (0)
- AGenome-WideAberrantRNASplicing inPatientswithAcute MyeloidLeukemia IdentifiesNovelPotentialDiseaseMarkers and Therapeutic Targets (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Edward A. Fox?
Edward A. Fox is affiliated with the following schools:
